GAMMAR INJ 165MG/ML 165 MG
IMMUNOGLOBULIN (HUMAN) : 165 MG · DIN 01915312 · ARMOUR PHARMACEUTICAL CO.
Health Canada status: CANCELLED POST MARKET
What is GAMMAR INJ 165MG/ML?
GAMMAR INJ 165MG/ML 165 MG contains IMMUNOGLOBULIN (HUMAN) : 165 MG. It is listed in the Health Canada Drug Product Database under DIN 01915312, held by ARMOUR PHARMACEUTICAL CO., supplied as LIQUID for INTRAMUSCULAR administration. Health Canada currently lists it as cancelled post market, status dated 15-Dec-1999. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 01915312 |
|---|---|
| Brand name | GAMMAR INJ 165MG/ML |
| Generic / active ingredient | IMMUNOGLOBULIN (HUMAN) : 165 MG |
| Manufacturer | ARMOUR PHARMACEUTICAL CO. |
| Strength | 165 MG |
| Dosage form | LIQUID |
| Route of administration | INTRAMUSCULAR |
| Schedule | Schedule D |
| ATC code | J06BA01 IMMUNOGLOBULINS, NORMAL HUMAN, FOR EXTRAVASC. ADM |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 15-Dec-1999 |
What can be used instead?
Other Canadian products sharing ATC code J06BA01 IMMUNOGLOBULINS, NORMAL HUMAN, FOR EXTRAVASC. ADM. 11 of 25 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CUVITRU | 200 MG | SOLUTION | TAKEDA CANADA INC | MARKETED | DIN 02461692 |
| GAMASTAN | 18 % | SOLUTION | GRIFOLS THERAPEUTICS LLC | MARKETED | DIN 02486598 |
| HIZENTRA | 200 MG | SOLUTION | CSL BEHRING CANADA INC | MARKETED | DIN 02463067 |
| HIZENTRA | 200 MG | SOLUTION | CSL BEHRING CANADA INC | MARKETED | DIN 02535424 |
| HIZENTRA | 200 MG | SOLUTION | CSL BEHRING CANADA INC | MARKETED | DIN 02498251 |
| HIZENTRA | 200 MG | SOLUTION | CSL BEHRING CANADA INC | MARKETED | DIN 02463059 |
| HYQVIA | 1600 UNIT / 10 ML | SOLUTION | TAKEDA CANADA INC | MARKETED | DIN 02524392 |
| HYQVIA | 200 UNIT / 1.25 ML | SOLUTION | TAKEDA CANADA INC | MARKETED | DIN 02524368 |
| HYQVIA | 30 G / 300 ML | SOLUTION | TAKEDA CANADA INC | MARKETED | DIN 02524406 |
| HYQVIA | 5 G / 50 ML | SOLUTION | TAKEDA CANADA INC | MARKETED | DIN 02524376 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.